Share on StockTwits
 

JPMorgan Chase & Co. hoisted their price target on shares of Merck & Co (NYSE:MRK) from $55.00 to $60.00 in a research note issued on Thursday, Analyst Ratings Network.com reports. JPMorgan Chase & Co.’s target price suggests a potential upside of 11.59% from the stock’s previous close.

MRK has been the subject of a number of other recent research reports. Analysts at Argus raised their price target on shares of Merck & Co from $54.00 to $62.00 in a research note to investors on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at SunTrust upgraded shares of Merck & Co from a “neutral” rating to a “buy” rating in a research note to investors on Tuesday. They now have a $62.00 price target on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Monday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $55.56.

Shares of Merck & Co (NYSE:MRK) traded up 0.45% on Thursday, hitting $53.77. The stock had a trading volume of 12,246,235 shares. Merck & Co has a 1-year low of $40.83 and a 1-year high of $55.20. The stock’s 50-day moving average is $51.10 and its 200-day moving average is $48.5. The company has a market cap of $157.1 billion and a price-to-earnings ratio of 35.97.

Merck & Co (NYSE:MRK) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.88 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.88. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $11.39 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was down 3.6% on a year-over-year basis. Analysts expect that Merck & Co will post $3.48 EPS for the current fiscal year.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.